Combination of HDAC inhibitors and Azacytidine for Cancer Cell Selective Targeting of Esophageal Cancer Cells

ABSTRACT: Esophageal cancers (ECs) are highly aggressive tumors with poor prognosis and few treatment options. This study investigated the possibility of treating esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) cells by inhibitors of broad and specific histone deacetylases (HDACi; SAHA, MS-275, FK228) and/or of DNMT (Azacytidine, AZA). Drug targets (HDAC1,2,3 and DNMT1) were present in non-neoplastic (HET-1A), ESCC (OE21) and EAC (OE33) cell lines. All cell lines responded to HDACi by reduced HDAC activity and increased histone acetylation as well as to AZA by up-regulation of p21. Expression of drug targets remained largely unaffected by HDACi and AZA treatment. Importantly, cell viability, apoptosis, cell cycle dynamics and DNA damage were only affected by HDACi and/o

ORGANISM(S): Homo sapiens

SUBMITTER: Hauke Busch 

PROVIDER: E-GEOD-57130 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress